Archiv
Archiv anzeigen:
bis


Gene Therapy for β-Thalassemia

David Green, MD, PhD reviewing Thompson AA et al. N Engl J Med 2018 Apr 19, Biffi A. N Engl J Med 2018 Apr 19

The need for long-term red cell transfusions was reduced without serious adverse events.


Managing Alopecia Caused by Adjuvant Endocrine Therapy for Breast Cancer

Andrew M. Kaunitz, MD reviewing Freites-Martinez A et al. JAMA Dermatol 2018 Apr 11, Trüeb RM. JAMA Dermatol 2018 Apr 11

Topical minoxidil was effective in patients with hair loss caused by tamoxifen or aromatase inhibitors.


The Pathogenesis of Expanded DLBCL Subsets

Michael E. Williams, MD, ScM reviewing Schmitz R et al. N Engl J Med 2018 Apr 12

Multiplatform molecular analysis revealed clinically relevant diffuse large B-cell lymphoma subtypes that may inform future therapeutic approaches.


Autologous Stem Cell Transplantation for POEMS Syndrome

David Green, MD, PhD reviewing Ohwada C et al. Blood 2018 Mar 29

Five-year progression-free survival was 63% and overall survival was 90%.


Are Deep Remissions Prognostic in Acute Myeloid Leukemia?

Michael E. Williams, MD, ScM reviewing Jongen-Lavrencic M et al. N Engl J Med 2018 Mar 29, Steensma DP and Ebert BL. N Engl J Med 2018 Mar 29

Achievement of undetectable residual disease was associated with lower relapse rate and improved survival after induction therapy.


Combining Targeted Therapies for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Tam CS et al. N Engl J Med 2018 Mar 29

Venetoclax plus ibrutinib provided high response rates in relapsed or refractory disease.


Multiparametric MRI Might Optimize Evaluation of Men with Elevated Prostate-Specific Antigen Levels

Allan S. Brett, MD reviewing Kasivisvanathan V et al. N Engl J Med 2018 Mar 19

But whether this technology will improve long-term outcomes is not yet clear.


Discontinuing Treatment for Chronic-Phase Chronic Myeloid Leukemia

Michael E. Williams, MD, ScM reviewing Mahon F-X et al. Ann Intern Med 2018 Feb 20

Half of patients remained in durable deep molecular remission after second-line therapy with nilotinib.


The 40th Annual San Antonio Breast Cancer Symposium

William J. Gradishar, MD

Highlights of the latest research


A Curative Regimen for Peripheral T-Cell Lymphoma?

Michael E. Williams, MD, ScM reviewing Fanale MA et al. Blood 2018 Mar 5

The addition of brentuximab vedotin to front-line chemotherapy provided durable remissions in half of CD30-positive patients.


Archiv
Seite von 67
Editorial Member Board Empfehlungen

PD Dr. med. Katja Zirlik

Hämatologie und internistische Onkologie
Tumorzentrum ZeTuP Chur

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Beim nicht kleinzelligen Lungenkarzinom (NSCLC) ist die Immuntherapie bereits in allen Therapielinien zugelassen. Die immunhistochemische Bestimmung der PD-L1-Expression auf den Tumorzellen ist derzeit der am besten validierte prädiktive Biomarker für die Therapie mit Checkpoint-Inhibitoren. Die vorliegende Studie untersuchte bei 848 Patienten mit NSCLC, ob die Mutationslast («tumor mutational burden», TMB), mittels «next-generation sequencing» (NGS) bestimmt, einen weiteren Marker darstellt, der die Wirksamkeit der Immuntherapie vorhersagen kann. Eine höhere Mutationslast war assoziiert mit einer Verbesserung im Hinblick auf die Ansprechrate sowie die Ansprechdauer. NSCLC-Patienten mit einer hohen Mutationslast profitieren demnach mehr von einer Immuntherapie.

Kommentar weiterlesen

Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.


Maintenance Immunotherapy for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Le Gouill S et al. N Engl J Med 2017 Sep 28

The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.


Adding Lorazepam to Haloperidol Might Help Alleviate Agitated Delirium in Advanced-Cancer Patients

Thomas L. Schwenk, MD reviewing Hui D et al. JAMA 2017 Sep 19, Pandharipande PP and Ely EW. JAMA 2017 Sep 19

Short-term reductions in agitation were helpful, but other components of delirium need further study.


Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2017 Sep 8

Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.


Axillary Dissection Unnecessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes

Henry Mark Kuerer, MD, PhD, FACS reviewing Giuliano AE et al. JAMA 2017 Sep 12, Livingston EH and Li HC. JAMA 2017 Sep 12

Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.


Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma

David H. Ilson, MD, PhD reviewing Alderson D et al. Lancet Oncol 2017 Sep

More intense preoperative chemotherapy fails to improve survival.


Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer

David H. Ilson, MD, PhD reviewing Overman MJ et al. Lancet Oncol 2017 Sep

The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.


Does Cutting Dietary Fat Affect Breast Cancer Outcomes?

Andrew M. Kaunitz, MD reviewing Chlebowski RT et al. J Clin Oncol 2017 Sep 1

Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.


Prothrombin Complex Concentrate for Bleeding from Direct Oral Anticoagulants

David Green, MD, PhD reviewing Majeed A et al. Blood 2017 Aug 23

Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.


Lung Cancer Rates Are Increasing Among Never-Smokers

Anne S. Tsao, MD reviewing Pelosof L et al. J Natl Cancer Inst 2017 Jul

From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.